Cataracts may be caused by crystallin interactions in lens

Article

Cataractogenesis may be the result of the interaction of crystallin-derived peptides with intact crystallins in the lens, according to a study published in the March 2008 issue of the Journal of Biological Chemistry.

Cataractogenesis may be the result of the interaction of crystallin-derived peptides with intact crystallins in the lens, according to a study published in the March 2008 issue of the Journal of Biological Chemistry.

Professor K. Krishna Sharma of the University of Missouri, US and colleagues used mass spectroscopy to identify 23 low molecular mass (<3.5 kDa) peptides in the urea-soluble fractions of young, aged, and aged cataract human lenses. The team synthesized two peptides found in the aged and aged cataract lenses, and one peptide found in all three, to study their interactions with intact crystallins and alcohol dehydrogenase.

The researchers discovered that, subsequent to interaction with intact crystallin subunits were less able to function as molecular chaperones, and that the presence of these peptides in place of hydrophobic residues eliminated their ability to induce crystalline aggregation and light scattering.

Thus the researchers concluded that cataracts may be caused by the increased amount of peptides in aged lenses interacting with intact crystallins and reducing chaperoning activity.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.